Figure 2.

Percentage of patients with clinically significant diarrhea or neutropenia, relative to exposure by cycle for MONARCH 1 and MONARCH 2. ^aAbemaciclib at 150 mg after amendment twice a day, plus fulvestrant. ^bAbemaciclib at 150 mg twice a day plus nonsteroidal aromatase inhibitor. Each light blue bar corresponds to the number of patients who received a cycle of treatment, representing total exposure by cycle. Each dark blue bar represents those with grade ≥2 diarrhea or grade ≥3 neutropenia. The number displayed above each dark blue bar is the percentage of patients with clinically significant diarrhea or neutropenia within each cycle. No grade ≥4 diarrhea was observed.